Dexcom

Dexcom Shares Outstanding

The The number of shares of Dexcom (DXCM) as of Nov 4, 2026 is 390.02 M. In the previous year, The number of shares was 390.02 M — a change of 0.00% (lower).

Shares Outstanding

390.02 M

YoY

0.00%

Last updated:

In 2025, Dexcom had 390.02 M outstanding stocks, a 0.00% change from the 390.02 M stocks in the previous year.

The Dexcom Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2023
390.02 M USD
Jan 1, 2024
390.02 M USD
Jan 1, 2025
390.02 M USD
Jan 1, 2026 (e)
398.90 USD
Jan 1, 2027 (e)
398.90 USD
Jan 1, 2028 (e)
398.90 USD
Jan 1, 2029 (e)
398.90 USD
Jan 1, 2030 (e)
398.90 USD
The Dexcom Shares Outstanding history
YEARShares OutstandingYoY
est398.900.00%
est398.900.00%
est398.900.00%
est398.900.00%
est398.90-100.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M0.00%
390.02 M+137.14 M%
284.40+3.49%
274.80+4.78%
262.26+15.27%
227.52+28.26%
177.39+50.04%
118.23+4.39%
113.25+3.96%
108.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dexcom Number of shares

Dexcom shares outstanding

The number of shares of Dexcom was 398.9 M in 2025. This indicates how many shares Dexcom is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2023
415.90 M Stocks
Jan 1, 2024
406.70 M Stocks
Jan 1, 2025
398.90 M Stocks
Jan 1, 2026 (e)
398.90 M Stocks
Jan 1, 2027 (e)
398.90 M Stocks
Jan 1, 2028 (e)
398.90 M Stocks
Jan 1, 2029 (e)
398.90 M Stocks
Jan 1, 2030 (e)
398.90 M Stocks

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Dexcom's Shares Outstanding

Dexcom's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Dexcom’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Dexcom’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Dexcom’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Dexcom stock

The number of shares of Dexcom is 390.02 M in 2025.

The number of shares of Dexcom changed from 390.02 M to 390.02 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Dexcom since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Dexcom

All Key Metrics — Dexcom